Home › Research › Down syndrome and Alzheimer's
Distinct Sensitivity of MRI Versus [ 18 F]FDG‐PET To Detect Cerebral Changes Across the Alzheimer's Continuum in Down Syndrome: A Multimodal Imaging Study
José Enrique Arriola‐Infante, Alejandra Omaira Morcillo-Nieto, María Franquesa‐Mullerat, Sára E. Zsadanyi, Lídia Vaqué‐Alcázar, Mateus Rozalem Aranha, Jose Allende Parra, Zili Zhao et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Abstract Background To date, limited evidence exists on the different sensitivity of MRI versus [ 18 F]FDG‐PET to detect early cerebral changes along the Alzheimer's disease (AD) continuum in Down syndrome (DS). Therefore, we aimed to characterize volume and metabolism alterations in adults with DS and compare their performance in detecting AD clinical stages. Method Cross‐sectional study, including 92 adults with DS from the Down‐Alzheimer Barcelona Neuroimaging Initiative (34 asymptomatic without amyloid pathology [aDS A−], 20 asymptomatic with amyloid pathology [aDS A+], 12 with prodromal AD [pDS], and 26 with AD dementia [dDS]; Table 1), who underwent 3T‐MRI and [ 18 F]FDG‐PET. Amyloid status in the aDS group was determined using amyloid‐PET (>20 centiloids, n = 29) or CSF Aβ42/Aβ40 ratio (<0.062, Lumipulse, n = 25). Brain volume and metabolism values were extracted using the Hammers atlas, normalizing MRI volumes by total intracranial volume and PET images using the pons as reference region. We calculated standardized‐β coefficients, adjusted for sex and scanner, to assess the effectiveness of MRI and PET scans in identifying stages of AD (aDS A− vs. aDS A+; aDS vs. symptomatic DS [sDS=pDS + dDS]). Result Progressive brain volume loss and metabolic decline were observed along the AD continuum in DS. Compared to aDS A−, aDS A+ exhibited lower volume in multiple regions, particularly in the frontal lobe. sDS individuals showed widespread atrophy, predominantly in temporal areas (Figure 1). In contrast, no significant hypometabolism was detected in aDS A+ compared to aDS A−, but sDS individuals exhibited global hypometabolism, primarily in temporo‐parietal regions (Figure 2). Conclusion Amyloid pathology in aDS individuals is linked to frontal‐predominant atrophy without clear hypometabolism. In symptomatic stages, both MRI and [ 18 F]FDG‐PET revealed widespread involvement, with atrophy predominating in temporal regions and hypometabolism in temporo‐parietal areas. Unlike in sporadic AD, no brain region showed greater hypometabolism than atrophy, suggesting alternative contributing factors in the general population. Our findings also suggest that MRI outperforms [ 18 F]FDG‐PET in identifying brain changes associated with AD clinical stages in DS, which has implications for early diagnosis and clinical trials.
What this study adds
Evidence grade: Low
The record lists 29 participants. This cross-sectional imaging study found progressive brain volume loss and metabolic decline along the Alzheimer's continuum in adults with Down syndrome. It compares how well MRI and FDG-PET detect disease stages but does not test any treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Arriola‐Infante, J. E., Morcillo-Nieto, A. O., Franquesa‐Mullerat, M., Zsadanyi, S. E., Vaqué‐Alcázar, L., Aranha, M. R., et al. (2025). Distinct Sensitivity of MRI Versus [ 18 F]FDG‐PET To Detect Cerebral Changes Across the Alzheimer's Continuum in Down Syndrome: A Multimodal Imaging Study. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_107114
Vancouver
Arriola‐Infante JE, Morcillo-Nieto AO, Franquesa‐Mullerat M, Zsadanyi SE, Vaqué‐Alcázar L, Aranha MR, et al. Distinct Sensitivity of MRI Versus [ 18 F]FDG‐PET To Detect Cerebral Changes Across the Alzheimer's Continuum in Down Syndrome: A Multimodal Imaging Study. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_107114.
BibTeX
@article{arriolainfante2025-294a9f95,
author = {Arriola‐Infante, José Enrique and Morcillo-Nieto, Alejandra Omaira and Franquesa‐Mullerat, María and Zsadanyi, Sára E. and Vaqué‐Alcázar, Lídia and Aranha, Mateus Rozalem and Parra, Jose Allende and Zhao, Zili and others},
title = {{Distinct Sensitivity of MRI Versus [ 18 F]FDG‐PET To Detect Cerebral Changes Across the Alzheimer's Continuum in Down Syndrome: A Multimodal Imaging Study}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_107114},
url = {https://doi.org/10.1002/alz70856_107114}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Abstract Background To date, limited evidence exists on the different sensitivity of MRI versus [ 18 F]FDG‐PET to detect early cerebral changes along the Alzheimer's disease (AD) continuum in Down syndrome (DS).
- Result Progressive brain volume loss and metabolic decline were observed along the AD continuum in DS.
- Compared to aDS A−, aDS A+ exhibited lower volume in multiple regions, particularly in the frontal lobe. sDS individuals showed widespread atrophy, predominantly in temporal areas (Figure 1).
- In contrast, no significant hypometabolism was detected in aDS A+ compared to aDS A−, but sDS individuals exhibited global hypometabolism, primarily in temporo‐parietal regions (Figure 2).
- In symptomatic stages, both MRI and [ 18 F]FDG‐PET revealed widespread involvement, with atrophy predominating in temporal regions and hypometabolism in temporo‐parietal areas.
Why it matters
This cross-sectional imaging study found progressive brain volume loss and metabolic decline along the Alzheimer's continuum in adults with Down syndrome. It compares how well MRI and FDG-PET detect disease stages but does not test any treatment, cure or prevention.
Study details
- Participants29
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 29 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Alexandre Bejanin: h-index 36 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Universitat de Barcelona: institution h-index 1,049 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.